12,372 trials
Atopic Dermatitis
Primary: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade…
Von Willebrand Disease (VWD)
Primary: Spontaneous Annualized Bleeding Rate (sABR) — 1.430; 1.040; 0.000; 3.022 spontaneous bleeds per year
Atopic Dermatitis
Primary: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade…
Recurrent Herpes Labialis
Primary: Duration of Episode (DOE) Was Measured in Hours (Using the Science 37 Platform), of a Single Treated Herpes Labialis (HL) Lesion — 66.5; 73.6 Hours — p=0.716
Graft Versus Host Disease (GVHD)
Primary: Overall Response Rate (ORR) to Acute Graft-versus-Host Disease (GVHD) Treatment — 60.0; 45.1 percentage of participants — p=0.034
Anemia, Iron Deficiency · Hyperphosphatemia · Renal Insufficiency, Chronic
Primary: Number of Participants Achieving a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality — 35; 46 Participants — p=.1602
ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (TESAEs) — 31; 63; 43; 16 Participants
Epilepsy in Children
Primary: Sleep Onset Latency — 22.80; 29.99 minutes
Brain Metastases
Primary: Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) Subject Level — 23.8; 34.1; 36.6; 82.6 percentage
Epilepsy
Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) — 42.1; 37.9 percentage of participants
Irritability Associated With Autism Spectrum Disorder (ASD)
Primary: Mean Change From Baseline to Week 8 in Aberrant Behavior Checklist - Irritability (ABC-I) Subscale Score — -10.1; -8.87 score on a scale — p=0.4597
Glomerulonephritis, Membranous
Primary: Percentage of Complete Remission — 4; 3 Participants
Homozygous Familial Hypercholesterolaemia (HoFH)
Primary: Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline — -53.910; -56.529; -51.633 Percent change from Baseline…
Asthma, Exercise-Induced
Primary: Maximum Percentage Fall From Post-dose, Pre-exercise Baseline in Forced Expiratory Volume in 1 Second (FEV₁) Observed up to 60 Minutes Post-exercise Challenge — 6.95…
Heart Failure With Preserved Ejection Fraction
Primary: Kansas City Cardiomyopathy Questionnaire -Total Symptom Score — 10.70; 9.81; 11.62 Points — p=0.537